The MG-QOL15 Japanese version: Validation and associations with clinical factors

Muscle and Nerve

Volumn 46, Issue 2, 2012, Pages 166-173

  masuda, Masayuki ^a   Utsugisawa, Kimiaki ^b   Suzuki, Shigeaki ^c   Nagane, Yuriko ^b   Kabasawa, Chiaki ^d   Suzuki, Yasushi ^e   Shimizu, Yuko ^d   Utsumi, Hiroya ^a   Fujihara, Kazuo ^f   Uchiyama, Shinichiro ^d   Suzuki, Norihiro ^c  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Department of Neurology   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SENDAI CITY MEDICAL CENTER   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cross sectional study; Health related quality of life; Myasthenia gravis; Questionnaire; Validity

Indexed keywords

PREDNISOLONE;

15 ITEM MYASTHENIA GRAVIS QUALITYOF LIFE SCALE; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CONCURRENT VALIDITY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUESTIONNAIRE; RELIABILITY; SELF CONCEPT; SHORT FORM 36; VALIDATION PROCESS;

ADULT; AGED; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TRANSLATIONS;

EID: 84863992083     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23398     Document Type: Article

References (27)

1. Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother 2009; 9: 351-358.
2. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291-298.
3. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71: 394-399.
4. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007; 21: 473-481.
5. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37: 141-149.
6. Padua L, Evoli A, Apirile I, Cliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001; 22: 363-369.
7. Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001; 24: 512-516.
8. Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve 2010; 42: 5-13.
9. Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. for the Task Force of the Medical Scientific Advisory Board of Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standers. Neurology 2000; 55: 16-23.
10. Padua L, Evoli A, Aprile I, Caliandro P, Batocchi AP, Punzi C, et al. Myasthenia gravis outcome measure: development and validation of disease-specific self-administered questionnaire. Neurol Sci 2002; 23: 59-68.
11. Mullins LL, Carpentier MY, Paul RH, Sanders DB, and the Muscle Study Group. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008; 38: 947-956.
12. Burns TM, Conaway MR, Cutter GR, Sanders DB, and the Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008; 38: 957-963.
13. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB, and the MG Composite and MG-QOL15 Study Group. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve 2010; 41: 219-226.
14. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB, and the MG Composite and MG-QOL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 2011; 43: 14-18.
15. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51: 1037-1044.
16. Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
17. Kojima M, Furukawa TA, Takahashi H, Kawai M, Nagaya T, Tokudome S. Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Res 2002; 110: 291-299.
18. Burns TM, Conaway MR, Cutter GR, Sanders DB, and the Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008; 38: 1553-1562.
19. Burns TM, Conaway M, Sanders DB, on behalf of the MG Composite and MG-QOL15 Study Group. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010; 74: 1434-1440.
20. Suzuki S, Utsugisawa K, Nagane Y, Satou T, Terayama Y, Suzuki N, et al. Classification of myasthenia gravis based on autoantibody status. Arch Neurol 2007; 64: 1121-1124.
21. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-1432.
22. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for process of cross-cultural adaptation of self-report measures. Spine 2000; 25: 3186-3139.
23. Fukuhara S, Suzukamo Y. Manual of SF-36v2 Japanese version. Kyoto: Institute for Health Outcomes and Process Evaluation Research; 2004.
24. Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, et al. Factors associated with depressive state in patients with myasthenia gravis: a multicenter cross-sectional study. BMJ Open 2011; 1: e000313.
25. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients. Eur Neurol 2010; 64: 186-190.
26. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 2011; 65: 16-22.
27. Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes 2010; 8: 129-138.